Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
AssigneesChugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology and Research
InventorsKatja FINK, Cheng-I WANG, Lisa Fong Poh NG, Laurent RENIA, Zenjiro SAMPEI, Xing'er Christine KOO
Life of this patent
Estimating the term…
Abstract
The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.
Claims11
A method for treating or preventing Dengue virus infection, comprising administering an antibody that binds to Zika virus, wherein the antibody comprises:
- (a) (i) HVR-H3 comprising the amino acid sequence GGX1ALFYDSYTTPX2DX3GSWWFDP, wherein X1 is R or E, X2 is R or F, X3 is G, D or L (SEQ ID NO:
- 42), (ii) HVR-L3 comprising the amino acid sequence QQFX1X2LPIT, wherein X1 is D, S or E, X2 is D or A (SEQ ID NO:
- 45), and (iii) HVR-H2 comprising the amino acid sequence VINPRGGSX1X2SAQKFQG, wherein X1 is T or R, X2 is A or R (SEQ ID NO:
- 41);
- (b) (i) HVR-H1 comprising the amino acid sequence SX1YX2H, wherein X1 is N or Y, X2 is I or M (SEQ ID NO:
- 40), (ii) HVR-H2 comprising the amino acid sequence VINPRGGSX1X2SAQKFQG, wherein X1 is T or R, X2 is A or R (SEQ ID NO:
- 41), and (iii) HVR-H3 comprising the amino acid sequence GGX1ALFYDSYTTPX2DX3GSWWFDP, wherein X1 is R or E, X2 is R or F, X3 is G, D or L (SEQ ID NO:
- 42);
- (c) (i) HVR-H1 comprising the amino acid sequence SX1YX2H, wherein X1 is N or Y, X2 is I or M (SEQ ID NO:
- 40), (ii) HVR-H2 comprising the amino acid sequence VINPRGGSX1X2SAQKFQG, wherein X1 is T or R, X2 is A or R (SEQ ID NO:
- 41), (iii) HVR-H3 comprising the amino acid sequence GGX1ALFYDSYTTPX2DX3GSWWFDP, wherein X1 is R or E, X2 is R or F, X3 is G, D or L (SEQ ID NO:
- 42), (iv) HVR-L1 comprising the amino acid sequence QASQX1IRX2YLN, wherein X1 is D or E, X2 is K or Q (SEQ ID NO:
- 43);
- (v) HVR-L2 comprising the amino acid sequence DASX1LKX2, wherein X1 is N or E, X2 is T or F (SEQ ID NO:
- 44);
- and (vi) HVR-L3 comprising the amino acid sequence QQFX1X2LPIT, wherein X1 is D, S or E, X2 is D or A (SEQ ID NO:
- 45);
- or
- (d) (i) HVR-L1 comprising the amino acid sequence QASQX1IRX2YLN, wherein X1 is D or E, X2 is K or Q (SEQ ID NO:
- 43);
- (ii) HVR-L2 comprising the amino acid sequence DASX1LKX2, wherein X1 is N or E, X2 is T or F (SEQ ID NO:
- 44);
- and (iii) HVR-L3 comprising the amino acid sequence QQFX1X2LPIT, wherein X1 is D, S or E, X2 is D or A (SEQ ID NO:
- 45),
- wherein the antibody is not an antibody comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 11, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 13, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 16, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 21, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 24, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 27.
A method for treating or preventing Dengue virus infection, comprising administering an antibody, comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs:
- 2-6;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs:
- 8-10;
- or (c) a VH sequence of any one of SEQ ID NOs:
- 2-6 and a VL sequence of any one of SEQ ID NOs:
- 8-10.
A method for treating or preventing Dengue virus infection, comprising administering an antibody that binds to Zika virus, wherein the antibody comprises:
- (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 12, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 15, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 20, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 21, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 24 and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 27.
Dependencies are inferred from the claim text.